Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-01-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: brainpriorchronicenrollmentheart
  Phrases that lowered it: dosedexamethasonemgweeksdaily
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 4.4% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 109 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past trials: 411 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 86.7% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer NCT01873833 · started 2013 · scored riskier than 78% of active trials terminated
• LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients NCT00632489 · started 2008 · scored riskier than 72% of active trials completed
• Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy NCT00759642 · started 2009 · scored riskier than 99% of active trials terminated
• Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer NCT01300962 · started 2011 · scored riskier than 75% of active trials completed
• Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC NCT03858972 · started 2019 · scored riskier than 81% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.